Newsletter | February 2, 2023

02.02.23 -- AAV Development And Manufacturing: Practical And Innovative Solutions

Practical, Innovative Solutions For AAV Development, Manufacturing

What are the current challenges and future promises of adeno-associated virus, lentivirus, and lipid nanoparticles in gene therapies? Explore case studies for AAV technology and manufacturing and strategies for navigating the regulatory environments in the U.S. and Europe.

Radiance Label-Free Monitoring Of AAV Transfection In HEK293 Cells

LumaCyte’s Radiance® instrument has the potential to improve the characterization of cell-based AAV transfection and production, improving the efficiency and accuracy of both processes and shortening development time.

Advancements In ADCs Using SMARTag Technology

Find a one-step tool kit to develop optimized ADCs and bioconjugates. SMARTag technology enables site-specific, controlled drug-protein conjugation and uses only naturally occurring modifications to proteins requiring minimal cell-line engineering.

Preparing For The Commercial-Scale Production Of Cell Therapies

It is important to identify which attributes are necessary to achieve commercial success in cell therapy and identify the manufacturing partner to bring your next therapy to clinic. Explore a few attributes that should be considered when planning manufacturing at scale for your cell therapy.